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Jeffrey M. Caves, PhD,a and Elliot L. Chaikof, MD, PhD,a,b,c Atlanta, Ga
Noncoronary atherosclerotic vascular disease, including symptomatic lower extremity peripheral arterial disease (PAD),
promises to extract a steadily rising medical and economic toll over the coming decades. Although drug-eluting stents
have led to substantial advances in the management of coronary atherosclerosis, endovascular treatment of noncoronary,
peripheral arterial lesions continues to yield high restenosis rates and early clinical failures. In this report, we review recent
developments in microfabrication and nanotechnology strategies that offer new opportunities for improving stent-based
technology for the treatment of more extensive and complex lesions. In this regard, stents with microfabricated reservoirs
for controlled temporal and spatial drug release have already been successfully applied to coronary lesions. Microfabri-
cated needles to pierce lesions and deliver therapeutics deep within the vascular wall represent an additional microscale
approach. At the nanoscale, investigators have primarily sought to alter the strut surface texture or coat the stent to
enhance inductive or conductive schemes for endothelialization and host artery integration. Nanotechnology research
that identifies promising strategies to limit restenosis through targeted drug delivery after angioplasty and stenting is also
reviewed. (J Vasc Surg 2006;44:1363-8.)Noncoronary atherosclerotic vascular disease affects 18
million people in the United States, and up to half of these
individuals have symptomatic lower extremity peripheral
arterial disease.1-3 During the next 20 years, it is estimated
that the number of cases of peripheral arterial disease will
double, with an anticipated dramatic increase in health care
costs and economic losses due to the rising incidence of
limb loss, disability, and death.4,5
The endovascular management of vascular disease
through the use of balloon/laser angioplasty, stenting, or
atherectomy offers a minimally invasive alternative to sur-
gical bypass, but unfortunately, the clinical effectiveness of
these strategies remains limited by a significant incidence of
restenosis.6-9 For example, primary patency rates for percu-
taneous angioplasty and stenting of femoropopliteal lesions
averages 61% at 1 year (47% to 86%), with 3-year patency
rates ranging from 61% for patients with discrete, focal
lesions of the superficial femoral artery to less than 30% for
those patients with more complex lesions or occlusions that
present with critical limb ischemia.10,11
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doi:10.1016/j.jvs.2006.08.046Of note, despite the success of drug-eluting stents for
the treatment of coronary artery disease, 24-month data
from the Sirolimus-Coated Cordis SMART Nitinol Self-
Expanding Stent for the Treatment of Obstructing Super-
ficial Femoral Artery Disease (SIROCCO) trial, which eval-
uated sirolimus-coated shape memory alloy recoverable
technology (SMART) stents for the treatment of superficial
femoral artery lesions, demonstrated restenosis rates of 40%
and 44% for slow and fast-release formulations, respec-
tively. These rates were not significantly different than
those observed in the control group treated with bare metal
stents.12
Apart from biologic differences between coronary and
peripheral arteries, these data emphasize that lesions repre-
sentative of peripheral arterial disease are more complex
and extensive than those associated with coronary artery
disease. Thus, the development of endovascular stents with
improved clinical performance characteristics remains a
critical need in the field. The application of evolving micro-
technologies and nanotechnologies in stent design is high-
lighted in this review.
IN-STENT RESTENOSIS AND LATE
THROMBOSIS
Major limitations of stent technology have included
in-stent restenosis and late thrombosis. Drug elution has
substantially reduced in-stent restenosis rates, with target
lesion revascularization reduced by 73% after 1 year for
paclitaxel-eluting stents13 and 75% after 270 days for
sirolimus-eluting stents.14 The extended durability of these
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the initially low restenosis rates may resurge as the effect of
drug elution diminishes. Moreover, restenosis rates remain
higher or unknown in some sites, such as the vertebral
artery,15 superficial femoral artery,16 and saphenous vein
grafts. Long, heavily calcified, or necrotic lesions also may
benefit from more advanced technologies.
Late stent thrombosis (30 days postprocedure) is a
rare complication (0% to 2% incidence) but leads to fatal
myocardial infarction in an estimated 45% of these cases.17
Thrombosis in bare metal stents is associated with several
mechanisms that interfere with strut endothelialization and
delayed healing, including radiation therapy, stenting of
highly necrotic plaques, disruption of plaques adjacent to
the stent, and stenting across the ostia of major arterial
branches.18
Concerns that drug-eluting stents may lead to a higher
rate of late thrombosis have been voiced because paclitaxel
and sirolimus slow endothelialization, resulting in subclin-
ical thrombus formation.19 Indeed, data outside of clinical
trials show higher drug-eluting stent thrombosis rates than
observed in clinical trials or with bare metal devices.17
Moreover, premature discontinuation of antiplatelet ther-
apy increases the late thrombosis rate to 29%.17 Hypersen-
sitivity to the poly-n-butyl methacrylate and polyethylene–
vinyl acetate copolymer coating the Cypher stent (Cordis
Corporation, Miami Lakes, Fla) also delays healing and has
been associated with fatal late thrombosis.20 Many technol-
ogies to combat thrombosis by promoting stent endothe-
lialization or elution of anticoagulants might be envisioned;
several of which are discussed. However, for any new
device, a relatively large clinical data set will be required to
substantiate any reduction in late thrombosis due to the
low occurrence of this complication.
MICROFABRICATED DRUG RESERVOIRS
Microfabrication technologies have improved in con-
junction with increased demand for minimally invasive
surgical treatments. The most pervasive microfabrication
technology in medical device manufacturing appears to be
laser machining, used in the fabrication of stents, embolic
filters, stent grafts, catheters, and other devices. Lasers can
Fig 1. Laser machining methods. A, After the direct-write
method, a pulsed laser is scanned over the workpiece usingmirrors.
B,Themasked-projectionmethod is used to process larger regions
of the workpiece with a wide, patterned beam.be used either via the direct write method where the beamis scanned over the workpiece, or the masked-projection
method where a wide beam is passed through a patterned
mask and regions of the workpiece are processed by the
patterned beam (Fig 1). In both methods, the laser is
pulsed at 1 kHz or faster, allowing the substrate to briefly
cool between exposures and avoiding melting. Each pulse
typically removes 0.1 to 0.5 m of material. Polymers and
metals can be readily cut with channels as thin as 50 to 100
m to form stents.
Two new stents, the Janus CarboStent (Sorin Bio-
medica Cardio S.p.A., Via Crescentino, Italy) and the
Conor stent (Conor Medsystems, Inc, Menlo Park, Calif),
contain microfabricated reservoirs for drug release. Com-
pared with polymer-coated stents, the drug reservoir con-
cept allows designers to select polymers based primarily on
biocompatibility, biodegradation, and drug elution prop-
erties, because the polymer coating adherence and lubricity
are less critical. In addition, both designs can contain more
drug than first-generation drug-eluting stents and release
the drug specifically toward the vascular wall (Fig 2).
In the Conor stent, distinct reservoirs are cut into
widened regions of the strut, and in the Janus CarboStent,
a continuous groove, or “sculpture,” is cut in the abluminal
face of the strut. The widened struts of the Conor stent are
inflexible, so stent expansion relies on “ductile hinge”
regions between the struts. Although geometrically more
complex, this design permits drug release on both the
abluminal and adluminal sides of the strut, whereas the
sculpture of the Janus CarboStent only releases the drug to
the abluminal side. Also, the distinct reservoirs of the
Conor stent may be more suitable than the continuous
groove in the Janus CarboStent for the controlled contain-
ment and elution of multiple drugs. The Conor stent
releases the drug from a fully degradable poly(lactic-
co-glycolic acid) matrix. In the case of the Janus design, the
drug is loaded directly into the sculptures with no polymer
matrix.
The Paclitaxel In-Stent Controlled Elution Study
(PISCES) of the Conor platform compared bare stainless
steel Conor stents to drug-loaded versions with different
rates of drug release and different dosages.21 Partly because
Fig 2. Drug-containing reservoirs permit more advanced drug-
release strategies.of the high level of control over elution kinetics, it was
icatio
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stent neointimal hyperplasia more than increased dose.
In vivo studies in pigs have also shown that healing can be
spatially controlled by leaving some reservoirs free of pac-
litaxel.22 The authors noted “islands” of healed tissue and
thickened neointima, which corresponded to regions of the
stent that were not loaded with paclitaxel.
In vitro, a high degree of control over paclitaxel
release kinetics was obtained by loading the polymer and
drug in layers within the reservoir, designed to degrade
sequentially.22 For example, biphasic kinetics could be
obtained by varying the concentration in subsequent layers.
Furthermore, use of a drug-free polymer “topcoat” pre-
cluded an initial burst of drug in the first 24 hours.22 The
CoStar stent, a cobalt chromium version of the original
Conor platform, has obtained Conformité Européene
(CE) mark clearance and is commercially available in
Europe, and the Cobalt Chromium Stent With Antipro-
liferative for Restenosis (CoSTAR) II clinical trial of the
stent for United States approval completed enrollment in
Fig 3. Left, A fabricated sample as cut from the metal fo
side views of an expanded stent.24 (Reprinted with th
©2004.)
Fig 4. Production of silicon micro-needles, as describe
lithographic methods are used to pattern the chromium
desired micro-needles (steps 1-3). A reactive ion etching t
protects regions of the silicon wafer, leaving a micro
subsequently serve as masters to form molds for the fabrlate April.Other microfabrication technologies may impact stent
technology in the future. The microelectrodischarge ma-
chining (EDM) technique, for example, removes material
with electrical pulses between an electrode and the work-
piece. Any conductive substrate can be machined, with
feature sizes as small as 25 m.23 The recent modification
of the EDM process to use arrays of electrodes in parallel
should allow the efficient batch fabrication of multiple
stents in parallel andmay offer higher precision and reliabil-
ity than laser machining (Fig 3).24
Stents fabricated from planar stainless steel foil dis-
played radial stiffness similar to commercial stents and
greater bending flexibility. In addition, helical stents with
inductive properties can be fabricated by EDM, poten-
tially enabling the stents to serve as antennas for wireless
communication. For example, “stentennas” could be inte-
grated with implantable microsystems to measure blood
pressure and flow rate.24
Fabrication techniques to decorate the adluminal face
of stent struts with microneedles, capable of piercing dense
th microelectrodischarge machining. Right, Angled and
mission of Journal of Microelectromechanical Systems
Henry.26 A silicon wafer is coated with chromium, and
ots, approximately the same diameter as the base of the
que is used to erode the silicon. The chromium dot array
e pattern (steps 4-5). Silicon microneedles arrays can
n of metal and polymer micro-needles arrays.27il wi
e perd by 
into d
echni
needlatherosclerotic lesions and delivering therapeutics to the
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tially, photolithography and chemical etching techniques
were borrowed from integrated circuits manufacturing to
construct sharp silicon microneedles that were 80 to 140
m tall. When applied in vitro to atherosclerotic rabbit iliac
artery tissue, the microneedles successfully transected the
arterial wall.25
Integrated circuit fabrication methods are most suit-
able for creating flat features on planar, silicon surfaces
(Fig 4).26,27 Thus, cylindrical metal or polymer stents
cannot be readily obtained using this approach, and alter-
nate technologies will be required to construct stents em-
bedded with microneedles. Indeed, the planar EDM pro-
cess could provide one strategy to generate a tubular stent
Fig 5. Hollow microneedles fabricated out of silicon, metal, and
glass imaged by optical and scanning electron microscopy. A,
Straight-walled metal microneedle from a 100-needle array fabri-
cated by electrodeposition onto a polymer mold (200 m tall). B,
Tip of a tapered, beveled, glass microneedle made by conventional
micropipette puller (900 m length shown). C, Tapered, metal
microneedle (500 m tall) from a 37-needle array made by elec-
trodeposition onto a polymeric mold. D, Array of tapered metal
micro-needles (500 m height) shown next to the tip of a 26
gauge hypodermic needle. (Reprinted with permission of the
National Academy of Sciences, USA ©2003.)27from flat sheets embeddedwithmicroneedles. Several otheradvanced microneedle technologies have been devel-
oped,27 but to date, the fabrication of a microneedle stent
has not been announced (Fig 5).
NANOTEXTURED STENT COATINGS
In addition to microscale surface features, nanoscale
texture through the deposition of nanocoatings may be
useful given the observation that surface topography can
promote vascular smooth muscle cell and endothelial cell
adherence and proliferation.28,29 Several such coatings
have been generated using a sol-gel process, in which a
colloidal suspension (sol) of metal or ceramic is applied to a
surface by dipping or spraying and subsequently bonded to
form a porous, highly textured coating. Hydroxyapatite30,31
and titania32 sol-gel coatings are under development. Studies
suggested that these coatings can significantly enhance cell
attachment, and the porosity of these coatings establish them
as potential candidates for drug elution.
Nanotextured coatings fit into a category of design
concepts that enhance endothelialization of stent struts and
may reduce late thrombosis. However, for a significant
impact, these devices will need to recruit and maintain an
endothelial layer under many of the common scenarios
where the risk of thrombosis is typically increased, examples
of which include an intervention that occurs in a previously
irradiated vessel or that which leads to significant plaque
disruption.
NANOPARTICLE-ENCAPSULATED DRUGS
Nanoparticle encapsulation may allow higher arterial
wall concentrations and residence times than traditional
drugs, two important factors for the prevention of resteno-
sis. In 1996, investigators found that balloon-catheter de-
livery of dexamethasone-loaded nanoparticles in a dog
model resulted in the continued presence of nanoparticles
in all three layers of the femoral artery wall after 7 days and
in the adventitial layer after 14 days.33 However, plasma
concentrations of the drug were not detectable after 3 days,
suggesting that systemic toxicity effects may be circum-
vented with localized, drug-laden nanoparticles. Subse-
quent work showed that the tissue concentration of similar
systems was increased by seven to ten times when the
surface of the nanoparticles was modified with a cationic
chemical species, which was postulated to interact with the
negatively charged glycosaminoglycans of the arterial
wall.34
In addition to this ionic interaction, nanoparticles func-
tionalized with antibodies have been shown to bind specif-
ically to either cross-linked fibrin in thrombus or tissue
factor, a transmembrane glycoprotein up-regulated in
smooth muscle cells after vascular injury. Tissue factor–
targeted nanoparticles, delivered locally with a balloon
catheter, were shown to enter the tunica media after bal-
loon overstretch injury and may also be useful for sustained
drug delivery.35,36 Local delivery of nanoparticles, com-
bined with ionic or antibody targeting strategies, may
therefore permit the sustained, high concentration drug
therapy required to prevent restenosis.
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not be required. Endothelial injury after balloon angio-
plasty creates a state of vascular hyperpermeability that
allows nanoparticles to enter the arterial wall selectively in
and around the target lesion.37 These authors showed that
doxorubicin-loaded nanoparticles could be delivered sub-
cutaneously to a balloon-injured carotid artery in a rat
model. High-pressure liquid chromatography showed sig-
nificantly higher tissue concentrations of the nanoparticles
in the injured artery compared with the contralateral con-
trol, and neointimal hyperplasia was reduced in a dose-
dependent manner.37 In addition, a nanoparticle formula-
tion of paclitaxel, administered intra-arterially immediately
after iliac artery stent placement in rabbits and again intra-
venously after 28 days, showed sustained suppression of
neointimal growth for 90 days.38 These studies suggest that
targeted nanoparticle therapy may be possible even without
balloon catheter delivery.
CONCLUSIONS
Investigation in a variety of areas at the microscale
and nanoscale has begun to impact stent design. Stents
equipped with microfabricated drug reservoirs are avail-
able in several countries and in clinical trials in the United
States. Additional microfabrication strategies may facilitate
the efficient batch fabrication of stents from planar foils or
the addition of microneedle features to stent struts. Nano-
porous and nanotextured coatings may enhance cell adhe-
sion, potentially reducing thrombosis, and may also allow
controlled drug elution without a polymer coating. Finally,
nanoencapsulated drugs, as an adjunct to stent technology,
may provide an alternate approach to drug eluting stents
for site-targeted drug delivery.
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